Detalles de la búsqueda
1.
Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy.
Oncologist;
27(2): 82-86, 2022 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641210
2.
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Cancer;
126(6): 1264-1273, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31860140
3.
Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia.
Oncologist;
24(2): 247-254, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30139841
4.
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Cancer;
124(2): 306-314, 2018 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28960265
5.
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Haematologica;
102(4): 719-727, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28034990
6.
Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.
Cancer;
122(15): 2379-88, 2016 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27171984
7.
Health care utilization and end-of-life care for older patients with acute myeloid leukemia.
Cancer;
121(16): 2840-8, 2015 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25926135
8.
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Blood;
120(23): 4649-52, 2012 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-23074281
9.
Improving access to vision rehabilitation care: implementation of the South East Ontario Vision Rehabilitation Service.
Can J Ophthalmol;
2023 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37743046
10.
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
Leuk Lymphoma;
63(6): 1428-1435, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35075985
11.
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
EJHaem;
3(2): 434-442, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35846042
12.
PD-1 inhibition in advanced myeloproliferative neoplasms.
Blood Adv;
5(23): 5086-5097, 2021 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34581778
13.
Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement.
Blood Adv;
4(1): 106-111, 2020 01 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31905241
14.
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.
Lancet Haematol;
7(2): e122-e133, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31837959
15.
Identifying community-dwelling older adults' vision loss during mobility assessments: A scoping review.
Can J Occup Ther;
86(2): 95-105, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30862231
16.
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.
Leukemia;
33(10): 2393-2402, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30923318
17.
MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts.
Mol Cell Biol;
22(8): 2871-81, 2002 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-11909979
18.
Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy.
Leukemia;
34(11): 3050-3054, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32678290
19.
Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.
Blood Adv;
4(13): 3136-3140, 2020 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32649766
20.
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Leuk Res;
37(9): 1016-20, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23773898